Patel Sandip I 4

4 · Akari Therapeutics Plc · Filed Apr 29, 2025

Form 4

Period: 2025-04-25

Director

Transactions

Award
Series A Warrants (Right to Buy)
2025-03-06$1.12/sh+44,642$49,999→ 44,642 total
Exercise: $0.87From: 2025-03-06Exp: 2026-03-06→ American Depositary Shares representing Ordinary Shares (44,642 underlying)
Award
American Depositary Shares representing Ordinary Shares
2025-03-06$1.12/sh+44,642$49,999→ 496,499 total
Award
Series B Warrants (Right to Buy)
2025-03-06$1.12/sh+44,642$49,999→ 44,642 total
Exercise: $0.87From: 2025-03-06Exp: 2030-03-06→ American Depositary Shares representing Ordinary Shares (44,642 underlying)

Holdings

American Depositary Shares representing Ordinary Shares
(indirect: By LLC)
19,880
American Depositary Shares representing Ordinary Shares
(indirect: By LLC)
13,901
American Depositary Shares representing Ordinary Shares
(indirect: By LLC)
20,219
American Depositary Shares representing Ordinary Shares
(indirect: By LLC)
6,250

Footnotes (2)

[F1]Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
[F2]On April 25, 2025, the Reporting Person acquired 44,642 ADS and accompanying Series A and Series B warrants to purchase up to 89,284 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant.

Documents

1 file